Sign in
Taking peoplePhase 2/3

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Key facts

Who runs it
Shanghai Jiaolian Drug Research and Development Co., Ltd
Where
China21 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
216 people, planned
Started
30 Jul 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • B007
  • Cyclosporin Capsules
Record updated
5 May 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy
  • Subjects with glomerular filtration rate(eGFR) ≥ 45 mL/min/1.73 m2
  • If taking Angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists/sodium-glucose cotransporter 2 inhibitors/endothelin inhibitors, a stable dose within 4 weeks before randomization
  • Subjects with 24-hour elevated urinary protein in accordance with the prescribed conditions
  • Subjects whose laboratory test results meet the prescribed standards during the screening period
  • Subjects who have fully understood this study and voluntarily signed the informed consent form;
  • Subjects who are able to follow the study protocol as judged by the investigator

Who cannot take part

  • Subjects with secondary membranous nephropathy or primary membranous nephropathy whose pathological reports suggest concomitant crescent bodies
  • Subjects identified by the investigator as previously resistant to CD20 monoclonal antibody or cyclosporine
  • Subjects who have received medication prescribed for membranous nephropathy
  • Subjects with concomitant prescribed diseases
  • Subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug
  • Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment
  • Pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug
  • For male subjects who have not been sterilized: those who do not consent to the use of barrier contraception during the study period and for at least 12 months after the last administration of the study drug, and who do not consent to the use of other contraceptive methods by their spouses
  • Subjects with a known history of severe allergic reactions to humanized monoclonal antibodies, or known allergies to any component of cyclosporine or B007
  • Subjects with positive hepatitis B surface antigen; those with positive hepatitis C virus antibody; those with a history of immunodeficiency or suffer from other acquired or congenital immunodeficiency diseases
  • Other conditions unsuitable for participation in this study determined by the Investigator
  • Subjects with CD4+ T lymphocyte count < 400 cells/μL

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy

The 2 groups in the trial

  • B007Treatment being tested
  • Cyclosporin CapsulesExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy.
Fit questions
Built from NCT06470191, who can take part
Record updated
5 May 2026